Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials
High PIV zenith during CRT strongly predicts poorer survival outcomes in patients with ESCC treated with combined immunotherapy and CRT. These peaks are associated with higher MLD, reduced interferon α response, interferon γ response and increased prevalence of Hippo pathway mutations.
Authors
- Hong Yang (ORCID: https://orcid.org/0000-0002-6007-9086)
- Mian Xi (ORCID: https://orcid.org/0000-0002-8088-0970)
- Yilu Gao
- Baoqing Chen (ORCID: https://orcid.org/0000-0001-9807-7425)
- Qianwen Liu (ORCID: https://orcid.org/0000-0002-4665-5673)
- Ruixi Wang (ORCID: https://orcid.org/0009-0005-4056-9618)
- Qiaoqiao Li (ORCID: https://orcid.org/0000-0002-6299-4966)
- Shiliang Liu (ORCID: https://orcid.org/0000-0001-5830-5171)
- Sha Zhou (ORCID: https://orcid.org/0000-0002-7468-1924)
- Xiaoyu Cheng (ORCID: https://orcid.org/0000-0001-5413-2859)
- Kongjia Luo
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1080/07853890.2025.2576639
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00